Overview

Arun J. Mohan is a member of the Intellectual Property Group. He focuses his practice on Hatch-Waxman and biosimilar patent litigation.

Before joining Schiff Hardin, Arun was an intellectual property litigation associate at a Wilmington, Del. law firm. He was a clinical research associate for a global contract research organization before attending law school.

  • Credentials

    Education

    • Michigan State University College of Law, J.D., 2014
      Michigan State Law Review, Associate Editor
      Trial Practice Institute
      Intellectual Property Law Society
      Saul Lefkowitz Trademark Moot Court Team (2013, 2014)
    • Cornell University, B.S., Biological Sciences, 2005

    Bar Admissions

    • Delaware
    • New York
    • U.S. Court of Appeals for the Third Circuit
    • U.S. District Court for the District of Delaware
      • Insights

        TITLE
        News Release

        Best Lawyers Recognizes 59 Schiff Attorneys, Six “Lawyers of the Year,” and 21 Ones to Watch

        Schiff Hardin LLP is pleased to announce that 59 attorneys have been listed in the 2021 edition of The Best Lawyers in America, with six attorneys also being named a “Lawyer of the Year” in their respective areas of practice and location.

        Alert

        If Successful, Teva Suit Could Decrease Generic Competition

        Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

        Alert

        FDA Rule Shifting Drugs to New Approval Pathway May Cause Continued Generics Delays

        The U.S. Food and Drug Administration (FDA) issued a final rule last week that broadened the scope of the Biologics Price Competition and Innovation Act (BPCIA) to include large proteins, even those that could have been previously governed by the Hatch-Waxman Act.

        Alert

        Will The Supreme Court End Venue Shopping In Patent Cases?

        The Supreme Court recently agreed to hear a challenge to the current interpretation of the venue statute in patent infringement cases.

        Article

        Other Publications

        • “Effects of Federal Circuit's Decision on Standard for Joint Infringement,” Delaware Business Court Insider (Dec. 2, 2015)
        • “Worldwide Accountability: The WTO's Failure to Create an Infrastructure that Delivers Pharmaceutical Drugs to Developing Countries,” Emory International Law Review (2015)
        • “District Court Considers Post-Octane Fitness Fee Awards,” Delaware Business Court Insider (Oct. 22, 2014)
        • “Process Stories: Patenting Natural Law Processes Under Prometheus—How Much Addition to a Patent Claim Is Enough?,” Journal of the Patent and Trademark Office Society (2014)
      • Citizenship

        Pro Bono Activities

        • Represented transgender inmates seeking to change their name based on a sincerely held gender identity
        • Represented inmates alleging violations of their civil rights pursuant to 42 U.S.C. § 1983